/
TIL
$7.21-$0.24 (-3.22%)live
Change$-364.19
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$50.5M
7M shares
52-week range
$5.67 – $25.55
8% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Instil Bio, Inc. Common Stock
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
www.instilbio.com- Employees
- 17
- IPO / List date
- Mar 19, 2021
- HQ
- DALLAS, TX
Held by traders on TradeandTell
No one on the platform currently holds TIL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 59,100 | $487.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-12-08 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded TIL yet.
